Compare PMEC & RKTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMEC | RKTO |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7M | 18.9M |
| IPO Year | 2021 | 2018 |
| Metric | PMEC | RKTO |
|---|---|---|
| Price | $0.30 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.8K | ★ 270.9K |
| Earning Date | 07-24-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.43 |
| 52 Week High | $1.37 | $1.19 |
| Indicator | PMEC | RKTO |
|---|---|---|
| Relative Strength Index (RSI) | 26.69 | 25.12 |
| Support Level | N/A | N/A |
| Resistance Level | $0.79 | $0.77 |
| Average True Range (ATR) | 0.05 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 7.34 | 9.07 |
Primech Holdings Ltd is a Singapore-based facilities services and AI robotics group with operations in Singapore and Hong Kong. Through its subsidiaries, the company provides integrated facilities management, cleaning and stewarding services to the public and private sectors, serving airports, educational institutions, healthcare facilities, commercial buildings and hospitality venues. It also develops HYTRON, an autonomous restroom-cleaning robot that uses AI perception and robotic manipulation. In addition, the company operates HomeHelpy, a digital platform for booking home services for consumers.
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.